Xiaohua Gong

6PUBLICATIONS
9CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)PharmacogenomicsAllergy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 11, 2026
Phase I safety, efficacy, and biomarker response evaluations of three oral PD-L1 inhibitors: INCB086550, INCB099280, and INCB099318.

|Apr 29, 2025
Exposure-response analyses of pemigatinib in patients with myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 rearrangement.

Xiaohua Gong, Ayman Akil, Boris Grinshpun

|Dec 09, 2024
Pharmacokinetics of Zilurgisertib With and Without Food from Single and Multiple Ascending Dose Phase 1 Studies in Healthy Adults.

Yan-Ou Yang, Xiaohua Gong, Jay Getsy

|Feb 26, 2024
Evaluation of the cardiac safety of parsaclisib, a selective PI3Kδ inhibitor, in patients with previously treated B-cell malignancies: Results from the CITADEL-101 study.

Jia Li, Xiaohua Gong, Xing Liu

|Apr 04, 2022
A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis.

Robert Bissonnette, Robert S Call, Tooraj Raoof

|Dec 24, 2021
Evaluation of the clinical cardiac safety of pemigatinib, a fibroblast growth factor receptor inhibitor, in participants with advanced malignancies.

Xiaohua Gong, Tao Ji, Xiang Liu

Pageof 1

Frequent Collaborators

1 joint publications

Robert Bissonnette

1 joint publications

Yan-Ou Yang

1 joint publications

Phillip Wang

1 joint publications

Hans Prenen